Evidence Hub

Analysis of the assortment and availability of drugs in medical technological documents regulating the acid-dependent diseases pharmacotherapy

O. Tkachova, H. Bielik, S. Stepanova, A. L. Shtroblia, M. V. Shtroblia, A. Taran

Likarska sprava, 2025

Abstract

Aim of the research. Analyse the assortment of anti-ulcer drugs on the pharmaceutical market of Ukraine for 2024, as well as their availability in medical technological documents confirming their clinical effectiveness and safety in the pharmacotherapy of peptic ulcer of the stomach and duodenum. Materials and methods. To analyze the assortment and prices of drugs for pharmacotherapy of peptic ulcer and duodenal ulcer on the pharmaceutical market of Ukraine, the State Register of Medicines of Ukraine and the online information service Tabletki.ua were used. Formal VEN analysis was performed based on availability of drugs in medical technological documents (MTD): the State Drug Formulary of Ukraine (SDFU, 16th edition), National Essential Medicines List of Ukraine (2023), Unified Clinical Protocol of Primary and Secondary (Specialized) Medical Care (UCPMC) for patients with peptic ulcer of the stomach and duodenum (2023) [11], British National Formulary (BNF) (2023). Results and discussion. Analysis of proton pump inhibitors and H2-histamine receptor antagonists on the pharmaceutical market of Ukraine in 2024 showed that there are 171 trade names (TN) of drugs on the market based on 9 INNs. The market is dominated by omeprazole (38 TN), pantoprazole (49 TN) and esomeprazole (34 TN). VEN analysis of available drugs for the treatment of peptic ulcer of the stomach and duodenum in four MTDs revealed that only 2 out of 9 drugs of this group are included in the National List of…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free